Role of von willebrand factor in tumour cell-induced platelet aggregation: Differential regulation by NO and prostacyclin

British Journal of Pharmacology

Volumn 134, Issue 5, 2001, Pages 1104-1112

  Jurasz, Paul ^a   Stewart, Michael W ^b   Radomski, Anna ^a   Khadour, Fadi ^a   Duszyk, Marek ^a   Radomski, Marek W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Thrombotics Inc   (Canada)

Author keywords

Adhesion; Aggregation; Glycoprotein Ib; Glycoprotein IIb IIIa; HT 1080 fibrosarcoma cells; Nitric oxide; Platelets; Prostacyclin; Solid phase von Willebrand factor

Indexed keywords

FIBRINOGEN; FIBRINOGEN RECEPTOR; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; S NITROSOGLUTATHIONE; VON WILLEBRAND FACTOR;

AGONIST; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TUMOR CELL;

EID: 0035159498     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704343     Document Type: Article

References (49)

1. Immunoquantitation of factor VIII-related antigen (von Willebrand factor antigen) in prostate cancer
2. Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition of studies with apyrase, hirudin, and phospholipase
3. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies
4. Platelet-vessel wall interaction: From the bedside to molecules
5. Mechanisms of enhanced intrahepatic metastasis in surfactant treated hampsters: An electron microscopy study
6. Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study
7. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (VWF) in patients with operable cervical cancer: Influence of surgical-pathological stage, tumor size, histologic type, and lymph node status
8. Antimetastatic effects associated with platelet reduction
9. Platelet-tumor cell interactions in mice. The role of platelets in the spread of malignant disease
10. Role of platelet membrane glycoprotein IIb-IIIa in agonist induced tyrosine phosphorylation of platelet proteins
11. Evidence that changes in platelet cyclic AMP levels regulate the fibrinogen receptor on human platelets
12. Activated-protein-C resistance in cancer patients
13. Prostacyclin: A potent antimetastatic agent
14. The role of platelet cyclooxygenase and lipoxygenase pathways in tumor cell induced platelet aggregation
15. Platelets and cancer metastasis: More than an epiphenomenon
16. Morphological analysis on microparticle generation in heparin-induced thrombocytopenia
17. Matrix metalloproteinases 2 in tumor cell-induced platelet aggregation: Regulation by nitric oxide
18. The effects of nitric oxide (NO) on platelet membrane receptor expression during activation with human α-thrombin
19. Responses to aggregating agents after cleavage of GPIb of human platelets by the o-sialoglycoprotein endoprotease from Pasteurella haemolytica-potental surrogates for Bernard-Soulier platelets?
20. Potential role of platelets in the pathogenesis of tumor metastasis
21. Blood platelet activation and membrane glycoprotein changes during extracorporel life support (ECLS). In vitro studies
22. Effects of prostacyclin on tumor cell-induced platelet aggregation
23. Effects of nitric oxide/EDRF on platelet surface glycoproteins
24. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation
25. Expression of tissue type plasmonogen activator inhibitor and von Willebrand factor in the supernatant of endothelial cell culture in response to the seeding of adenocarcinoma cell line HRT-18
26. An abnormal glycoprotein pattern in 3 cases of Glanzmann thrombasthemia
27. Deficiency of von Willebrand's Factor - Cleaving protease in patients with disseminated malignancies
28. Von Willebrand factor in plasma of patients with advanced stages of larynx cancer
29. Glycoprotein IIIa is phosphorylated in intact human platelets
30. Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide
31. Protection from tumor necrosis factor-mediated cytolysis by platelets
32. Thrombospondin in malignant and non-malignant breast tissue
33. Elevation of camp, but not cGMP, inhibits thrombin-stimulated tyrosine phosphorylation in human platelets
34. Human colorectal adenocarcinoma cells: Differential nitric oxide synthesis determines their ability to aggregate platelets
35. An improved method for washing platelets with prostacyclin
36. The anti-Aggregating properties of vascular endothelium: Interactions between prostacyclin nitric oxide
37. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets
38. Structure and function of von Willebrand factor
39. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood
40. Comparative pharmacology of analogues of S-nitroso-N-acetyl-DL-penicillamine on human platelets
41. Regulation of natural killer cell function by nonlymphoid cells
42. 3 in tumor-cell induced platelet aggregation
43. Platelet activation by a novel solid-phase agonist: Effects of VWF immobilized on polystyrene beads
44. Von Willebrand factor in head and neck cancer
45. Evaluation of the coagulation/fibrinolysis balance in patients with colorectal cancer
46. Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets
47. Platelet glycoprotein Ibb is phosphorylated on serine 166 by cyclic AMP-dependent protein kinase
48. Decreased adhesion of ginat (Bernard Soulier) platelets to subendothelium: Further implications on the role of the von Willebrand factor in hemostasis
49. Glycoprotein lbb is the only phosphorylated major membrane glycoprotein in human platelets